Introduction
Myocardial oxygen consumption (MVO 2 ) directly reflects myocardial oxygen supply and demand. The purpose of this study is to test the ability of a cardiovascular magnetic resonance (CMR) method to determine changes in myocardial MVO 2 during pharmacologically-induced hyperemia in a canine stenosis model.
Methods
13 dogs were divided into four groups, which can be seen in Table 1 . Stenosis was created by an occluder around the proximal left-anterior descending (LAD) and stenosis severity was confirmed via Doppler flow reduction. MVO 2 was calculated by the Fick principle: MVO 2 ∝ OEF × MBF, in which OEF is the oxygen extraction fraction and MBF represents myocardial blood flow.
OEF during hyperemia was determined by a two compartment model with measured myocardial T2 that is measured with a 2-D segmented turbo spin-echo (TSE) sequence [1] . This sequence was performed several times at rest and during either Dipyridamole-induced vasodilation or Dobutamine-induced hyperemia. Rest OEF was assumed to be 0.6, which is based on values measured in normal dogs using an arterial and coronary sinus blood sampling approach at rest [2] . MBF values, both at rest and during pharmaceutical stress, were determined with the quantitative first-pass perfusion CMR method. Firstpass images were denoised and MBF maps were created with an algorithm that was developed and validated in our laboratory [3] . MVO 2 values were determined in the stenotic LAD perfused anterior region and the remote leftcircumflex (LCX) perfused inferior region.
Results
MVO 2 results can be seen in Figure 1 . As expected, Dobutamine causes a dramatic increase in MVO 2 , while injection of Dipyridamole shows only a moderate effect.
In the anterior area with LAD stenosis, after the injection of Dipyridamole, a small increase in MVO 2 was observed at 13.8% and 10.7% for the 70% and 90% stenosis groups, respectively. With Dobutamine, MVO 2 increased significantly at 57.9% and 35% for the 50% and 70-90% stenosis groups, respectively.
In the remote normal LCX perfused region, Dipyridamole induced moderate increases in MVO 2 at 49.9% and 17.3% in the 70% and 90% stenosis groups, respectively. This is different from conventional wisdom that Dipyridamole would induce no changes in MVO 2 , but is consistent with a report using adenosine injection in dogs [4] . As expected, Dobutamine induced much higher changes in 
Conclusion
Our CMR method can non-invasively quantify regional myocardial MVO 2 . Determination of the changes in MVO 2 is important in the diagnosis and management of patients with coronary artery disease.
